Investor Highlights

Pharmaxis Strengthens Drug Discovery Capability as its Technology Platform Continues to Deliver

  • Head of Chemistry (ex Boehringer Ingelheim) recruited to Drug Discovery leadership team
  • Two leading scientists join Scientific Advisory Board
  • Amine Oxidase chemistry platform delivers five lead candidates in fibrosis and inflammation over four years as Pharmaxis states ambition to expand its drug discovery activities into new technologies and take select programs into phase 2 clinical trials.

 

Read full media release - pdf

Pharmaxis Capability

Pharmaxis CEO Gary Phillips discusses the Company’s drug discovery team. (Watch the video here)

Pharmaxis Drug Discovery

Pharmaxis CEO Gary Phillips discusses the Company’s approach to drug discovery and the diseases on which it focuses. (Watch the video here)

Pharmaxis Business Model

Pharmaxis CEO Gary Phillips discusses the Company’s approach to commercialising its drug discoveries. (Watch the video here)

Notice of 2017 Annual General Meeting

The 2017 Annual General Meeting of Pharmaxis will be held at 2.30pm on 13 November 2017 at Christie Conference Centre, 3 Spring Street Sydney.

The notice of meeting, explanatory statement and proxy form were mailed to shareholders on 12 October 2017. The notice of meeting together with a sample proxy form is available here.

The 2017 statutory annual report is available here.